CompletedPHASE2, PHASE3NCT00891306

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Studying Familial lipoprotein lipase deficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Amsterdam Molecular Therapeutics
Principal Investigator
Daniel Gaudet, MD, Ph.D.
ECOGENE-21 Clinical Trial Center / Centre de santé et de services sociaux de Chicoutimi, Chicoutimi Hospital, Quebec, Canada
Intervention
Alipogene Tiparvovec (AMT-011), Human LPL [S447X](genetic)
Enrollment
5 enrolled
Eligibility
18 years · All sexes
Timeline
2009 – 2011

Study locations (2)

Collaborators

The Clinical Trial Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00891306 on ClinicalTrials.gov

Other trials for Familial lipoprotein lipase deficiency

Additional recruiting or active studies for the same condition.

See all trials for Familial lipoprotein lipase deficiency →

← Back to all trials